论文信息 - Efficacy of niraparib by timing of surgery and residual disease: a post-hoc analysis of patients in the PRIMA/ENGOT-OV26/GOG-3012 study - 字舞流文

Efficacy of niraparib by timing of surgery and residual disease: a post-hoc analysis of patients in the PRIMA/ENGOT-OV26/GOG-3012 study

Richard G. Moore | B. Monk | Aalok Kumar | I. Tusquets | M. Shahin | S. Hietanen | J. Fuentes | B. Slomovitz | J. Pérez-Fidalgo | F. Selle | I. Malinowska | W. Bradley | D. O’Malley | C. Vulsteke | A. Dørum | P. Calvert | K. Baumann | T. Levy | D. Gupta | R. O’Cearbhaill | C. Mccormick | G. Artioli | Y. Li | F. Forget | A. González-Martín

[1] F. Selle,et al. 177 Efficacy of niraparib by timing of surgery and residual disease: a post-hoc analysis of patients in the PRIMA/ENGOT-OV26/GOG-3012 study , 2021, Ovarian cancer.